Immunological aspects of metronomic chemotherapy regimens
- Authors: Efremova N.A1,2, Novik A.V1,2, Zozulya A.Y.1, Nekhaeva T.L1, Danilova A.B1, Emelyanova N.V1, Girdyuk D.V1, Gafton G.I1, Baldueva I.A1
-
Affiliations:
- N.N. Petrov National Medical Research Center of Oncology
- St. Petersburg State Pediatric Medical University
- Issue: Vol 28, No 7 (2021)
- Pages: 81-86
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313183
- DOI: https://doi.org/10.18565/pharmateca.2021.7.81-86
- ID: 313183
Cite item
Abstract
Full Text
About the authors
N. A Efremova
N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical University
Email: petrovcenter.celltech@gmail.com
St. Petersburg, Russia
A. V Novik
N.N. Petrov National Medical Research Center of Oncology; St. Petersburg State Pediatric Medical UniversitySt. Petersburg, Russia
A. Yu Zozulya
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
T. L Nekhaeva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. B Danilova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
N. V Emelyanova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
D. V Girdyuk
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
G. I Gafton
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
I. A Baldueva
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
References
- Jo V.Y, Fletcher C.D.M. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology. 2014;46(2):95-104. Dot 10.1097/PAT.0000000000000050.
- Авдонкина Н.А., Данилова А.Б., Нехаева Т.Л., Балдуева И.А.Современные представления о клональной эволюции сарком. Вопросы онкологии. 2019;65(6):798-806.
- Kareva I., Waxman D. J, Klement G. L. Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer letters. 2015;358(2):100-6. doi: 10.1016/j.canlet.2014.12.039.
- Butt A.Q., Mills K.H.G. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2014;33(38):4623-31. doi: 10.1038/onc.2013.432.
- Pipia N., et al. Autologous dendritic-cell vaccine based on cancer-testis antigens ‘CaTeVac' in the treatment of soft tissue sarcoma. Ann Oncol. 2018;29:viii410-viii411. doi: 10.1093/annonc/ mdy288.026.
- Новик А.В., Гирдюк Д.В., Кузнецова А.И., Балдуева И.А. Способ определения значимости различий результатов измерения субпопуляции лимфоцитов методом проточной цитофлюориметрии. Патент № RU 2720411C1 от29.04.2020.
- Zhong H., et al. Low dose cyclophosphamide modulates tumor microenvironment by TGF-fi signaling pathway. Int J MolSci. 2020;21(3):957. doi: 10.3390/ijms21030957.
- Ghiringhelli F., et al. Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-48. doi: 10.1007/s00262-006-0225-8.
- Schmittnaegel M., et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670. Doi: 10.1126/ scitranslmed.aak9670.
- Балдуева И.А., Данилова А.Б., Новик А.В. и др. Дендритные клетки, активированные раковотестикулярными антигенами (РТА+), в лечении метастатических сарком мягких тканей. Вопросы онкологии. 2014;60(6):700-6.
- Danilova A., et al. Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells. Clin Sarcoma Res. 2020;10:3. doi: 10.1186/s13569-020-0125-2.
- Desar I.M.E., Fleuren E.D.G., van der Graaf W.T.A. Systemic Treatment for Adults with Synovial Sarcoma. Curr Treat Option Oncol. 2018;19(2):13. doi: 10.1007/s11864-018-0525-1.